On April 7, 2026, Tyler Van Buren from TD Cowen initiated a Hold rating on Soleno Therapeutics, Inc. (NASDAQ: SLNO), with a target price of $53. This decision reflects a cautious stance amidst the company’s fluctuating stock performance and recent earnings surprises. Investors now have to weigh the potential risks against the recent optimistic EPS figures, which have shown a significant upside.
Market / Price Action
Soleno Therapeutics’ stock closed at $52.35, a slight change of $0.10 or approximately 0.19%. This marginal gain occurs against a backdrop of significant volatility, characterized by a beta of -2.805, indicating an inverse relationship with market movements. Over the past week, SLNO has seen price fluctuations within a range that reflects investor uncertainty. The stock’s 52-week high of $57.83 and a low of $3.87 underline the volatility inherent to Soleno’s trading. A notable trading volume of 17,282,040 shares, far exceeding the average volume of 1,689,125, suggests heightened investor interest or reaction to broader market signals.
Short- and Long-Term Performance
Over the past month, SLNO’s performance has been less than stellar, recording a drop of 11.21%. In a broader context, the stock has declined 33.21% over the last 90 days and is also down 4.91% year-on-year. These figures may be concerning for investors, especially when considering the stock’s overall high volatility, with a weekly volatility rate of 5.28% and a monthly rate of 5.69%. A higher average trading volume over the past ten days (14,378,788) compared to the last three months (2,881,359) indicates a surge in trading activity, potentially driven by strategic positioning ahead of earnings announcements.
Earnings / Financials
In its latest earnings report dated November 4, 2025, Soleno Therapeutics announced an earnings per share (EPS) of $0.47, significantly beating the estimated EPS of $0.0575, resulting in an extraordinary surprise factor of 717.39%. This robust performance marks a turnaround from the previous quarter, where the actual EPS yielded a disappointing -$0.09 against an expected -$0.53. Such a dramatic swing suggests improved operational efficiencies or market conditions that could bode well for upcoming quarters.
Analyst / Consensus View
The consensus surrounding SLNO has been cautiously optimistic. According to data from TD Cowen, the stock currently holds eight ratings—six “Buy” and two “Hold,” with no “Sell” ratings present. The average price target stands at $96.75, further supported by a high target of $120 and a low of $53. These ratings suggest a generally favorable outlook from analysts, although the recent Hold designation implies some hesitation, potentially due to market conditions or competitive factors.
Stock Grading or Fundamental View
The Stocks Telegraph grading score for Soleno Therapeutics is 53, indicating sound fundamentals, albeit with room for improvement. This score reflects the company’s current operational health and investment profile based on various financial metrics and market analysis, suggesting that while the firm has strong capabilities, investors should remain alert to ongoing market dynamics and company developments.
Conclusion
For investors eyeing Soleno Therapeutics, the recent Hold rating indicates a strategic pause amidst volatility and mixed earnings metrics. The stock might appeal to those willing to take on some risk in exchange for potential upside, especially considering the robust earnings surprise. However, its erratic price history and recent downward trends necessitate caution. This stock may suit long-term growth investors who recognize potential in a volatile environment but are also mindful of the risks inherent to biopharmaceutical investments. As Soleno continues to evolve, it remains on the radar for those interested in both short-term trades and long-term holds, especially as it navigates the challenges and opportunities within its sector.